8 results about "Hypermetabolism" patented technology

The invention discloses a nutrition allocation recommendation method used after a surgical operation, and relates to the technical field of clinical medicine, and the method comprises the following specific steps: stage division, stage preparation formula design, supply adjustment and stage conversion recommendation and monitoring, and scheme optimization. Postoperative nutrition allocation is divided into three stages, namely an adaptive feeding stage, a transitional nutrition stage and a comprehensive nutrition support stage, and an enteral nutrition preparation with a specific ratio is designed for each stage, so that high synchronization of nutrition supply and postoperative physiological metabolism characteristics is ensured; in the first stage, a hypotonic formula mainly comprising oligopeptide and free amino acid is adopted, so that the intestinal mucosa function is effectively protected, and intestinal peristalsis is promoted; in the second stage, by increasing the proportion of intact protein and soluble dietary fibers, energy and protein supply is improved, and the high metabolism requirement of the body is met; in the third stage, comprehensive and sufficient nutrition support is provided, and tissue repair and physical recovery are accelerated.

This disclosure describes the characteristics of the “energetic” cancer stem cell (e-CSC) phenotype. This distinct sub-population of cancer stem cells (CSCs) has a unique energetic profile compared to bulk CSCs, being more glycolitic, having higher mitochondrial mass and elevated oxidative metabolism. e-CSCs also show an increased capacity to undergo cell cycle progression, enhanced anchorage-independent growth, and ALDH-positivity. The e-CSC phenotype presents new targets for cancer therapeutics, and in particular the anti-oxidant response, mitochondrial energy production, and mitochondrial biogenesis of e-CSCs makes them highly susceptible to mitochondrial inhibitors that target e-CSC anti-oxidant response, mitochondrial energy production, and mitochondrial biogenesis. Gene products for e-CSCs are disclosed, as well as classes of mitochondrial inhibiting therapeutic agents. Also disclosed are methods for identifying and separating e-CSCs front bulk cell populations.

This invention relates to a weight-loss composition and its application. The weight-loss composition comprises the following components in parts by weight: 10-20 parts flaxseed oil powder, 10-20 parts coconut water powder, 5-10 parts galactooligosaccharides, 1-5 parts white kidney bean-potato complex extract, 1-5 parts psyllium husk powder, and 0.1-1 parts epigallocatechin gallate. The weight-loss composition of this invention amplifies the efficacy of individual components through multi-dimensional synergistic effects of enhanced energy metabolism, blocked fat breakdown, regulated gut microbiota, and controlled blood sugar and appetite, ultimately achieving a synergistic effect of improved metabolism and weight loss.

The invention provides a self-adaptive digital comprehensive intervention method and system for schizophrenia with metabolic syndrome patients, and relates to the technical field of medical health management. Metabolic indexes such as diet, exercise, body weight, blood pressure and blood sugar are collected, and a metabolic risk assessment model is constructed in combination with drug use types and doses in an electronic medical record so as to determine a metabolic risk level; according to a cognitive score self-adaptive interface presentation mode, the intervention scheme is split into micro-tasks to be pushed and executed; when the patient completes the micro-task, a result is synchronized to the family supporter, and integral incentive is carried out; in the follow-up visit stage, metabolic index changes are continuously monitored, abnormal trends are recognized, early warning reports are generated, and the early warning reports are pushed to medical staff after being confirmed by patients so as to trigger timely medical intervention. According to the invention, closed-loop intervention integrating metabolism management, medication risk adjustment, cognitive adaptation interaction and family support excitation is realized, and the accuracy and effectiveness of metabolism risk control are improved.

The invention provides a metabolic acidosis risk assessment method and device, electronic equipment and a storage medium. The method comprises the following steps: allocating an initial metabolic acidosis risk level to a target patient based on initial medical data of the target patient, and determining an initial detection item set of the target patient based on the initial metabolic acidosis risk level; wherein the metabolic acidosis risk grade is divided into high risk, medium risk and low risk; dynamically updating the metabolic acidosis risk level of the target patient and the matched detection item set based on the real-time medical data corresponding to the detection item set of the target patient, and dynamically updating the metabolic acidosis risk level of the target patient and the matched detection item set based on the real-time metabolic acidosis risk level of the target patient and the real-time medical data corresponding to the detection item set. And carrying out metabolic acidosis risk early warning. The accuracy and efficiency of metabolic acidosis risk assessment can be improved, and then the medical safety and efficiency are greatly improved.

Compositions and methods for administering ketone bodies to a subject include a ketone body or ketone body precursor complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

The application provides an AKG-containing anti-aging functional food raw material with improved metabolic absorption rate, which is composed of the following components in parts by weight: diketopiperazine (AKG) 10-30 parts, black pepper extract 1-5 parts, turmeric 5-15 parts, and glutathione 8-20 parts; wherein the content of piperine in the black pepper extract is not less than 95%; and the glutathione is reduced glutathione with a purity of not less than 98.0%. The application takes AKG as a core synergistic absorption carrier, fully utilizes its inherent properties of regulating intestinal microenvironment, promoting intestinal mucosal repair, and activating absorption-related signal pathways, and forms a closed-loop synergy with the metabolic enzyme inhibition of black pepper extract, the intestinal anti-inflammatory effect of turmeric extract, and the antioxidant protection effect of glutathione, so as to crack the oral absorption barrier of the three core functional components from multiple dimensions and improve the metabolic absorption rate.